The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the α‐fetoprotein status

Recently, p53 gene aberrations have been recognized as a relevant factor in hepatocarcinogenesis, in tumors from both high‐risk and low‐risk areas. Because p53 gene mutations typically result in increased p53 levels in tumor cells, this cellular protein might become immunogenic during tumor development. To test this hypothesis, we have analyzed sera from 80 European patients with hepatocellular carcinoma for the presence of p53 antibodies. For this purpose we developed an immunoblot assay using recombinant p53 as antigen. Sixty‐seven sera from patients with different acute and chronic liver diseases were used as controls. In addition, serum α‐fetoprotein assays were performed. Circulating antibodies against p53 were found in 25% (20 of 80) of the sera from patients with hepatocellular carcinoma but not in various nonmalignant liver diseases The association of p53 antibodies with malignancy was highly significant (p < 0.00003). In 73.8% (59 of 80) of the hepatocellular carcinoma sera the α‐fetoprotein levels were elevated. Among the 21 α‐fetoprotein–negative hepatocellular carcinoma sera, 5 were found to contain p53 antibodies (23.8%). In conclusion, an antibody response against p53 developed in a significant proportion of patients with hepatocellular carcinoma but not in those with nonmalignant liver diseases. Serological testing for p53 antibodies gives the opportunity to identify a subgroup of patients with hepatocellular carcinoma not detected by conventional tests for serum α‐fetoprotein. (HEPATOLOGY 1993;18:559–565.)

[1]  D. Lane,et al.  Mutant conformation of p53. Precise epitope mapping using a filamentous phage epitope library. , 1992, Journal of molecular biology.

[2]  K. Okuda,et al.  Hepatocellular carcinoma: Recent progress , 1992, Hepatology.

[3]  J. Marks,et al.  Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[4]  P. Scheuer,et al.  p53 codon 249ser mutations in hepatocellular carcinoma patients with low aflatoxin exposure , 1992, The Lancet.

[5]  J. Wands,et al.  p53 mutation in hepatocellular carcinoma after aflatoxin exposure , 1991, The Lancet.

[6]  M. Colombo,et al.  Hepatocellular carcinoma in Italian patients with cirrhosis. , 1991, The New England journal of medicine.

[7]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[8]  A. Levine,et al.  The p53 tumour suppressor gene , 1991, Nature.

[9]  R. A. Metcalf,et al.  Mutational hot spot in the p53 gene in human hepatocellular carcinomas , 1991, Nature.

[10]  J. Wands,et al.  Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa , 1991, Nature.

[11]  C. S. Lee,et al.  Molecular analysis of the p53 alleles in primary hepatocellular carcinomas and cell lines. , 1991, Oncogene.

[12]  Kenzo Kobayashi,et al.  Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis , 1990, Hepatology.

[13]  D. Lane,et al.  Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. , 1990, The EMBO journal.

[14]  K. Isselbacher,et al.  Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[15]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.

[16]  D. Ledbetter,et al.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. , 1989, Science.

[17]  A. Levine,et al.  Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation , 1989, Journal of virology.

[18]  R. Beasley.  Hepatitis B virus. The major etiology of hepatocellular carcinoma , 1988, Cancer.

[19]  K. Chandrasekaran,et al.  Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B‐cell lymphoma , 1987, International journal of cancer.

[20]  H. Blum,et al.  Interaction of aflatoxin and hepatitis B virus in the pathogenesis of hepatocellular carcinoma. , 1986, Life sciences.

[21]  L. Banks,et al.  Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. , 1986, European journal of biochemistry.

[22]  H. Hsu,et al.  Serum alpha-fetoprotein in the early stage of human hepatocellular carcinoma. , 1984, Gastroenterology.

[23]  D. Pim,et al.  Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer , 1982, International journal of cancer.

[24]  T. Yamane,et al.  Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. , 1982, Cancer research.

[25]  H. Wepsic,et al.  Alpha-fetoprotein and its relevance to human disease. , 1979, Gastroenterology.

[26]  F. Studier,et al.  Use of T7 RNA polymerase to direct expression of cloned genes. , 1990, Methods in enzymology.

[27]  J. Groopman,et al.  Aflatoxin exposure in human populations: measurements and relationship to cancer. , 1988, Critical reviews in toxicology.

[28]  P. Johnson,et al.  Cirrhosis and the aetiology of hepatocellular carcinoma. , 1987, Journal of hepatology.

[29]  D. Schachter.  Fluidity and Function of Hepatocyte Plasma Membranes , 1984, Hepatology.